NCT03983824 2026-05-13Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid LeukemiaNational Cancer Institute (NCI)Phase 1 Active not recruiting48 enrolled